文献速递贫血与红细胞疾病血栓与止血

遗传性出血性毛细血管扩张症的出血管理

How I treat bleeding in hereditary hemorrhagic telangiectasia.
PubMed 文献 · Blood · 2024-01-01

遗传性出血性毛细血管扩张症(HHT)是最常见的遗传性出血性疾病之一,毛细血管扩张性出血主要表现为反复鼻衄和慢性消化道出血。虽无监管机构批准的特效药,但多项大型研究(含随机对照试验)已证实抗纤溶药对轻中度出血、全身抗血管生成药(泊马度胺、贝伐珠单抗)对中重度出血安全有效。本文通过4例患者病例,结合已发表数据与临床经验,给出抗纤溶、抗血管生成及缺铁性贫血管理的现代循证指导。

要点

  • 抗纤溶药对HHT轻中度出血安全有效,随机对照试验已证实。
  • 泊马度胺、贝伐珠单抗等抗血管生成药对中重度出血安全有效。
  • HHT出血管理正从反复姑息性操作转向有效的全身药物治疗。

核心结论

  • 多项大型研究(含随机对照试验)证实抗纤溶药与全身抗血管生成药治疗HHT出血安全有效,推动治疗模式从反复姑息性操作转向全身药物治疗。

研究设计与样本

  • 本文为基于已发表数据与广泛临床经验的治疗指导性综述,采用4例患者病例说明HHT相关出血最常见和最棘手的表现。

主要发现

  • HHT影响约1/5000人群,是全球第二常见的遗传性出血性疾病。
  • 毛细血管扩张性出血主要表现为反复鼻衄和慢性消化道出血,是HHT最常见和最重要的表现。
  • HHT相关出血可导致显著心理社会负担和可能严重的缺铁性贫血。
  • 目前尚无监管机构批准的治疗HHT的药物。

关键数值与推荐

  • 抗纤溶药用于轻中度出血表现,安全性有效性经多项大型研究(含随机对照试验)证实。
  • 泊马度胺和贝伐珠单抗等全身抗血管生成药用于中重度出血,安全性有效性经多项大型研究(含随机对照试验)证实。

临床怎么用

  • 本文以4例病例为线索,就抗纤溶治疗、抗血管生成治疗及缺铁性贫血管理给出覆盖HHT疾病严重程度谱的现代循证方法指导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hereditary hemorrhagic telangiectasia (HHT; Osler-Weber-Rendu disease) affects 1 in 5000 persons, making it the second most common inherited bleeding disorder worldwide. Telangiectatic bleeding, primarily causing recurrent epistaxis and chronic gastrointestinal bleeding, is the most common and most important manifestation of this multisystem vascular disorder. HHT-associated bleeding results in substantial psychosocial morbidity and iron deficiency anemia that may be severe. Although there remain no regulatory agency-approved therapies for HHT, multiple large studies, including randomized controlled trials, have demonstrated the safety and efficacy of antifibrinolytics for mild-to-moderate bleeding manifestations and systemic antiangiogenic drugs including pomalidomide and bevacizumab for moderate-to-severe bleeding. This has led to a recent paradigm shift away from repetitive temporizing procedural management toward effective systemic medical therapeutics to treat bleeding in HHT. In this article, 4 patient cases are used to illustrate the most common and most challenging presentations of HHT-associated bleeding that hematologists are likely to encounter in daily practice. Built on a framework of published data and supported by extensive clinical experience, guidance is given for modern evidence-based approaches to antifibrinolytic therapy, antiangiogenic therapy, and iron deficiency anemia management across the HHT disease severity spectrum.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H. How I treat bleeding in hereditary hemorrhagic telangiectasia. Blood. 2024. PMID: 38864625. doi:10.1182/blood.2023021765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。